77 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
dividend income” if certain other requirements are met. Qualified dividend income is generally taxable at rates not in excess of the long-term capital … on the sale or other disposition of ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
of options and awards under existing equity incentive plans described in, the Registration Statement and the Prospectus), short-term debt or long … -term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
) -20.1 -13.8 UAS7 (CFB) -19.6 -11.7 BTK is expressed on haematopoietic cells including B cells, myeloid cells, platelets3 potential long-term safety … -KIT is expressed on haematopoetic stem cells, melanocytes, CNS and germ cells 4 Hair discolouration, urticaria, neutropenia Unknown impact of long-term mast
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
. In addition to this approach, inhibition of C5aR by oral small molecules may provide the ease of administration required for effective long-term treatment … long-term chronic toxicology studies, to enable longer-term dosing of INF904 for chronic inflammatory diseases. We initially plan to develop INF904
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
and plasma concentrations Sustained long-term control over C5a/C5aR activation in a variety of chronic inflammatory diseases Convenient oral
6-K
EX-99.1
cd7fp
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
dd05s30vgc1s05nmy
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
7cx2a9
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
424B5
d9znoni7jcnrlqb64m3
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
plpcemsvwsb0oo8i dfc
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
5wsqt6as5lzj5
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
p6s8nz wu
13 Apr 23
Current report (foreign)
4:01pm
424B5
ewy3ruh6q 5ffkojkx8
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
7ndy5k
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
5qxzqylaf7ybc
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
bbvc3cm2
9 Nov 22
Current report (foreign)
7:53am
6-K
EX-99.1
tc0 33ci2hbr
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
b9f0pg1v4r94e
5 Aug 22
Current report (foreign)
6:07am